B6.Cg-Tg(Col6a1-cre)1Gkl/Flmg
| Status | Available to order |
| EMMA ID | EM:05102 |
| International strain name | B6.Cg-Tg(Col6a1-cre)1Gkl/Flmg |
| Alternative name | CollagenVI-Cre [CBA.B6-Tg(Col6a1-cre)444Gkl/Flmg] |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Col6a1-cre)1Gkl, |
| Gene/Transgene symbol | Tg(Col6a1-cre)1Gkl |
Information from provider
| Provider | George Kollias |
| Provider affiliation | B.S.R.C. |
| Genetic information | The transgene contains a 7.5 kb of collagen VI enhancer/promoter, nuclear localization sequence-modified Cre recombinase and a 2.1 kb fragment from the human growth hormone gene. |
| Phenotypic information | Tool used together with conditional systems for specific expression of the targeted gene in synovial fibroblasts, articular chondrocytes, skeletal myocytes, intestinal myofibroblasts, dermal fibroblasts, and keratinocytes. |
| Breeding history | The strain is backcrossed in C57BL/6J for at least 10 generations. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | B.S.R.C. Alexander Fleming, Vari, Greece |
| Animals used for archiving | heterozygous C57BL/6, wild-type 0 |
| Stage of embryos | 2-cell |
Literature references
- Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases.;Armaka Maria, Apostolaki Maria, Jacques Peggy, Kontoyiannis Dimitris L, Elewaut Dirk, Kollias George, ;2008;The Journal of experimental medicine;205;331-7; 18250193